427 related articles for article (PubMed ID: 22425914)
1. Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer.
Leung EY; Scott HR; McMillan DC
J Thorac Oncol; 2012 Apr; 7(4):655-62. PubMed ID: 22425914
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment Modified Glasgow Prognostic Score Predicts Clinical Outcomes After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer.
Kishi T; Matsuo Y; Ueki N; Iizuka Y; Nakamura A; Sakanaka K; Mizowaki T; Hiraoka M
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(3):619-26. PubMed ID: 26068494
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the Glasgow Prognostic Score (GPS) and the modified Glasgow Prognostic Score (mGPS) in evaluating the prognosis of patients with operable and inoperable non-small cell lung cancer.
Fan H; Shao ZY; Xiao YY; Xie ZH; Chen W; Xie H; Qin GY; Zhao NQ
J Cancer Res Clin Oncol; 2016 Jun; 142(6):1285-97. PubMed ID: 26864695
[TBL] [Abstract][Full Text] [Related]
4. The relationship between the insulin-like growth factor-1 axis, weight loss, an inflammation-based score and survival in patients with inoperable non-small cell lung cancer.
Meek CL; Wallace AM; Forrest LM; McMillan DC
Clin Nutr; 2010 Apr; 29(2):206-9. PubMed ID: 19748165
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of the high-sensitivity modified Glasgow prognostic score in patients with resectable non-small cell lung cancer.
Osugi J; Muto S; Matsumura Y; Higuchi M; Suzuki H; Gotoh M
J Cancer Res Ther; 2016; 12(2):945-51. PubMed ID: 27461679
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the prognostic value of MUST, ECOG-PS, mGPS and CT derived body composition analysis in patients with advanced lung cancer.
Abbass T; Dolan RD; MacLeod N; Horgan PG; Laird BJ; McMillan DC
Clin Nutr ESPEN; 2020 Dec; 40():349-356. PubMed ID: 33183562
[TBL] [Abstract][Full Text] [Related]
7. A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer.
Forrest LM; McMillan DC; McArdle CS; Angerson WJ; Dagg K; Scott HR
Br J Cancer; 2005 May; 92(10):1834-6. PubMed ID: 15870712
[TBL] [Abstract][Full Text] [Related]
8. Inflammation-based scoring is a useful prognostic predictor of pulmonary resection for elderly patients with clinical stage I non-small-cell lung cancer.
Miyazaki T; Yamasaki N; Tsuchiya T; Matsumoto K; Kunizaki M; Taniguchi D; Nagayasu T
Eur J Cardiothorac Surg; 2015 Apr; 47(4):e140-5. PubMed ID: 25548132
[TBL] [Abstract][Full Text] [Related]
9. Value of the Glasgow Prognostic Score as a Prognostic Factor in Resectable Non-Small Cell Lung Cancer.
Yotsukura M; Ohtsuka T; Kaseda K; Kamiyama I; Hayashi Y; Asamura H
J Thorac Oncol; 2016 Aug; 11(8):1311-1318. PubMed ID: 27234603
[TBL] [Abstract][Full Text] [Related]
10. "How Long Have I Got?"-A Prospective Cohort Study Comparing Validated Prognostic Factors for Use in Patients with Advanced Cancer.
Simmons C; McMillan DC; Tuck S; Graham C; McKeown A; Bennett M; O'Neill C; Wilcock A; Usborne C; Fearon KC; Fallon M; Laird BJ;
Oncologist; 2019 Sep; 24(9):e960-e967. PubMed ID: 30975922
[TBL] [Abstract][Full Text] [Related]
11. Prognostic validation of the body mass index, airflow obstruction, dyspnea, and exercise capacity (BODE) index in inoperable non-small-cell lung cancer.
Denehy L; Hornsby WE; Herndon JE; Thomas S; Ready NE; Granger CL; Valera L; Kenjale AA; Eves ND; Jones LW
J Thorac Oncol; 2013 Dec; 8(12):1545-50. PubMed ID: 24389436
[TBL] [Abstract][Full Text] [Related]
12. Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).
Roncolato FT; Berton-Rigaud D; O'Connell R; Lanceley A; Sehouli J; Buizen L; Okamoto A; Aotani E; Lorusso D; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Hilpert F; Ledermann JA; Kaminsky MC; Stockler MR; King MT; Friedlander M
Gynecol Oncol; 2018 Jan; 148(1):36-41. PubMed ID: 29107348
[TBL] [Abstract][Full Text] [Related]
13. Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors.
Lee SJ; Lee JI; Nam DH; Ahn YC; Han JH; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2013 Feb; 8(2):185-91. PubMed ID: 23328548
[TBL] [Abstract][Full Text] [Related]
14. Modified Glasgow prognostic score is an independent prognostic factor in patients with cervical cancer undergoing chemoradiotherapy.
Xiao Y; Ren YK; Cheng HJ; Wang L; Luo SX
Int J Clin Exp Pathol; 2015; 8(5):5273-81. PubMed ID: 26191228
[TBL] [Abstract][Full Text] [Related]
15. A laboratory prognostic index model for patients with advanced non-small cell lung cancer.
Ulas A; Turkoz FP; Silay K; Tokluoglu S; Avci N; Oksuzoglu B; Alkis N
PLoS One; 2014; 9(12):e114471. PubMed ID: 25474743
[TBL] [Abstract][Full Text] [Related]
16. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study.
Proctor MJ; Morrison DS; Talwar D; Balmer SM; Fletcher CD; O'Reilly DS; Foulis AK; Horgan PG; McMillan DC
Eur J Cancer; 2011 Nov; 47(17):2633-41. PubMed ID: 21724383
[TBL] [Abstract][Full Text] [Related]
17. Prognosis in advanced lung cancer--A prospective study examining key clinicopathological factors.
Simmons CP; Koinis F; Fallon MT; Fearon KC; Bowden J; Solheim TS; Gronberg BH; McMillan DC; Gioulbasanis I; Laird BJ
Lung Cancer; 2015 Jun; 88(3):304-9. PubMed ID: 25870155
[TBL] [Abstract][Full Text] [Related]
18. The Glasgow prognostic score as a prognostic factor in patients with advanced non-small cell lung cancer treated with cisplatin-based first-line chemotherapy.
Jiang AG; Lu HY
J Chemother; 2015 Feb; 27(1):35-9. PubMed ID: 24716851
[TBL] [Abstract][Full Text] [Related]
19. The inflammation-based modified Glasgow Prognostic Score in patients with vulvar cancer.
Hefler-Frischmuth K; Seebacher V; Polterauer S; Tempfer C; Reinthaller A; Hefler L
Eur J Obstet Gynecol Reprod Biol; 2010 Mar; 149(1):102-5. PubMed ID: 20080329
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors.
Takamori S; Takada K; Shimokawa M; Matsubara T; Fujishita T; Ito K; Toyozawa R; Yamaguchi M; Okamoto T; Yoneshima Y; Tanaka K; Okamoto I; Tagawa T; Mori M
Lung Cancer; 2021 Feb; 152():27-33. PubMed ID: 33341085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
